Recursion Pharmaceuticals, Inc.
RXRX
$4.54
$0.225.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.69M | 64.60M | 59.79M | 58.84M | 65.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.69M | 64.60M | 59.79M | 58.84M | 65.18M |
| Cost of Revenue | 547.14M | 498.07M | 432.40M | 359.66M | 327.90M |
| Gross Profit | -503.45M | -433.47M | -372.61M | -300.82M | -262.71M |
| SG&A Expenses | 220.23M | 216.35M | 201.53M | 178.29M | 132.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 767.36M | 714.42M | 633.93M | 537.95M | 460.54M |
| Operating Income | -723.67M | -649.83M | -574.14M | -479.11M | -395.36M |
| Income Before Tax | -715.69M | -649.12M | -575.28M | -464.79M | -382.95M |
| Income Tax Expenses | -148.00K | 16.00K | -507.00K | -1.13M | -5.20M |
| Earnings from Continuing Operations | -715.54 | -649.13 | -574.78 | -463.66 | -377.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -715.54M | -649.13M | -574.78M | -463.66M | -377.75M |
| EBIT | -723.67M | -649.83M | -574.14M | -479.11M | -395.36M |
| EBITDA | -646.50M | -586.50M | -525.69M | -442.62M | -364.26M |
| EPS Basic | -1.81 | -1.79 | -1.78 | -1.66 | -1.55 |
| Normalized Basic EPS | -1.13 | -1.12 | -1.11 | -1.04 | -0.98 |
| EPS Diluted | -1.81 | -1.79 | -1.78 | -1.66 | -1.55 |
| Normalized Diluted EPS | -1.13 | -1.12 | -1.11 | -1.04 | -0.98 |
| Average Basic Shares Outstanding | 1.60B | 1.44B | 1.26B | 1.10B | 983.96M |
| Average Diluted Shares Outstanding | 1.60B | 1.44B | 1.26B | 1.10B | 983.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |